S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Bargain in Today's Market (SHOCKING) (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Bargain in Today's Market (SHOCKING) (Ad)pixel
Myanmar executions revive pressure for more sanctions
3 Stocks Set to Lead the Nasdaq Bull Market
Stocks higher on Wall Street; economic worries hit oil price
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Bargain in Today's Market (SHOCKING) (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Bargain in Today's Market (SHOCKING) (Ad)pixel
Myanmar executions revive pressure for more sanctions
3 Stocks Set to Lead the Nasdaq Bull Market
Stocks higher on Wall Street; economic worries hit oil price
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Bargain in Today's Market (SHOCKING) (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Bargain in Today's Market (SHOCKING) (Ad)pixel
Myanmar executions revive pressure for more sanctions
3 Stocks Set to Lead the Nasdaq Bull Market
Stocks higher on Wall Street; economic worries hit oil price
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Bargain in Today's Market (SHOCKING) (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Bargain in Today's Market (SHOCKING) (Ad)pixel
Myanmar executions revive pressure for more sanctions
3 Stocks Set to Lead the Nasdaq Bull Market
Stocks higher on Wall Street; economic worries hit oil price
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
NASDAQ:NBIX

Neurocrine Biosciences - NBIX Stock Forecast, Price & News

$107.39
+1.76 (+1.67%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$104.75
$107.50
50-Day Range
$88.93
$107.66
52-Week Range
$71.88
$109.26
Volume
739,381 shs
Average Volume
796,386 shs
Market Capitalization
$10.27 billion
P/E Ratio
976.36
Dividend Yield
N/A
Price Target
$113.60

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
5.8% Upside
$113.60 Price Target
Short Interest
Healthy
2.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.79
Upright™ Environmental Score
News Sentiment
0.79mentions of Neurocrine Biosciences in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$75,400 Sold Last Quarter
Proj. Earnings Growth
120.45%
From $1.76 to $3.88 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

858th out of 1,125 stocks

Biological Products, Except Diagnostic Industry

135th out of 179 stocks

NBIX stock logo

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Wall Street Analyst Weigh In

NBIX has been the topic of several research analyst reports. Robert W. Baird increased their target price on Neurocrine Biosciences from $117.00 to $125.00 in a report on Friday, August 5th. Morgan Stanley raised their price target on Neurocrine Biosciences from $100.00 to $102.00 and gave the company an "equal weight" rating in a report on Friday, July 15th. Barclays raised their price target on Neurocrine Biosciences from $110.00 to $113.00 and gave the company an "overweight" rating in a report on Friday, August 5th. StockNews.com upgraded Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Monday, August 8th. Finally, Wedbush reiterated an "outperform" rating on shares of Neurocrine Biosciences in a report on Thursday, April 28th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $113.60.

Neurocrine Biosciences Stock Up 1.7 %

Shares of Neurocrine Biosciences stock opened at $107.39 on Tuesday. The business's 50 day simple moving average is $96.83 and its 200 day simple moving average is $92.23. Neurocrine Biosciences has a 52-week low of $71.88 and a 52-week high of $109.26. The firm has a market cap of $10.27 billion, a PE ratio of 976.36 and a beta of 0.59. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.47 and a current ratio of 3.57.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Julie Cooke sold 754 shares of the firm's stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $100.00, for a total value of $75,400.00. Following the completion of the transaction, the insider now directly owns 16,918 shares in the company, valued at $1,691,800. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.40% of the company's stock.

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Stock News Headlines

See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Company Calendar

Last Earnings
11/01/2021
Today
8/15/2022
Next Earnings (Estimated)
11/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$113.60
High Stock Price Forecast
$154.00
Low Stock Price Forecast
$76.00
Forecasted Upside/Downside
+5.8%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
17 Analysts

Profitability

Net Income
$89.60 million
Pretax Margin
1.14%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$1.26 per share
Book Value
$14.48 per share

Miscellaneous

Free Float
91,431,000
Market Cap
$10.27 billion
Optionable
Optionable
Beta
0.59














NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NBIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NBIX, but not buy additional shares or sell existing shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price forecast for 2022?

17 equities research analysts have issued 12 month price targets for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $76.00 to $154.00. On average, they expect the company's stock price to reach $113.60 in the next year. This suggests a possible upside of 5.9% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2022?

Neurocrine Biosciences' stock was trading at $85.17 at the beginning of the year. Since then, NBIX stock has increased by 25.9% and is now trading at $107.24.
View the best growth stocks for 2022 here
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our NBIX earnings forecast
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings results on Monday, November, 1st. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by $0.28. The firm had revenue of $296 million for the quarter, compared to analyst estimates of $297.02 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 0.88% and a net margin of 0.94%. The firm's revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.62) EPS.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.52%), Congress Asset Management Co. MA (1.12%), Pictet Asset Management SA (1.12%), Brown Advisory Inc. (1.08%), Northern Trust Corp (0.91%) and California Public Employees Retirement System (0.67%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $107.24.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $10.26 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.11 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

The company employs 900 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.